Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $38.92, for a total transaction of $450,732.52. Following the transaction, the chief financial officer now owns 112,933 shares of the company’s stock, valued at $4,395,352.36. This trade represents a 9.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total value of $283,039.64.
• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total transaction of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98.

Hims & Hers Health Trading Down 4.4 %

Hims & Hers Health stock opened at $40.36 on Friday. The business has a 50-day moving average of $30.02 and a 200-day moving average of $23.12. The firm has a market capitalization of $8.82 billion, a P/E ratio of 91.72 and a beta of 1.35. Hims & Hers Health, Inc. has a 1 year low of $9.14 and a 1 year high of $44.43.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.04) EPS. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC raised its position in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. Stonekeep Investments LLC grew its holdings in Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after acquiring an additional 882 shares during the last quarter. Principal Securities Inc. raised its position in Hims & Hers Health by 48.2% during the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock worth $74,000 after purchasing an additional 1,002 shares during the last quarter. Victory Capital Management Inc. raised its position in shares of Hims & Hers Health by 1.9% during the fourth quarter. Victory Capital Management Inc. now owns 52,579 shares of the company’s stock worth $1,271,000 after acquiring an additional 1,002 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC increased their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.